Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Licenses MultiGen's Dx Panel

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem said today that it has licensed exclusive rights to market MultiGen Diagnostics' antenatal infectious disease tests in New York and non-exclusive rights to the market them in other US territories.

Enzo will validate and seek approval for MultiGen's multiplex Antenatal Infectious Disease panel and for a thrombophilia panel after they clear New York, New Jersey, and CLIA requirements and after it secures third-party reimbursement.

New York City-based Enzo said that it hopes to make the panel available in the second half of this year.

MultiGen's antenatal panel tests for simultaneous infection of certain bacterial, viral, or fungal pathogens using one specimen. The thrombogenic panel detects multiple mutations that can detect if an individual has a genetic predisposition to blood clotting.

MultiGen's DNA sequencing-based technology increases the "accuracy and utility" of its diagnostic tests, MultiGen Founder and President T. Vinayagamoorthy said in a statement.

Financial terms of the agreement were not released.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.